Annie Zhang
YOU?
Author Swipe
View article: Role and limits of minimally invasive esophagectomy for benign disease: a scoping review
Role and limits of minimally invasive esophagectomy for benign disease: a scoping review Open
View article: Impact of Diet and Gut Microbiome on Nonhuman Primate Models of Age-Related Macular Degeneration
Impact of Diet and Gut Microbiome on Nonhuman Primate Models of Age-Related Macular Degeneration Open
View article: Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control–matched, phase 4 clinical study (BALISTAD)
Dupilumab treatment restores lesional and nonlesional skin barrier function in adults and adolescents with atopic dermatitis irrespective of the filaggrin genotype: Results from an open-label, healthy-control–matched, phase 4 clinical study (BALISTAD) Open
View article: Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis
Real-world treatment outcomes of systemic treatments for moderate-to-severe atopic dermatitis in children aged less than 12 years: 2-year results from PEDIatric STudy in Atopic Dermatitis Open
Dupilumab was associated with numerically greater outcomes and higher adherence than cyclosporine or methotrexate.
View article: Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis
Dupilumab Improves Skin Lipid Barrier in Pediatric Patients With Moderate-to-Severe Atopic Dermatitis Open
View article: Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis
Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis Open
The trial was registered with ClinicalTrials.gov with ID number NCT03346434 on November 17, 2017. INFOGRAPHIC.
View article: Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli
Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli Open
Introduction Chronic itch is a central symptom of atopic dermatitis. Cutaneous afferent neurons express receptors interleukins (IL)-4, IL-13, and IL-33, which are type 2 cytokines that are elevated in atopic dermatitis. These neuronal cyto…
View article: Measurement of Happiness: Refined Approaches to the Evaluation of Happiness as a Complex Emotion
Measurement of Happiness: Refined Approaches to the Evaluation of Happiness as a Complex Emotion Open
Happiness as a sophisticated human emotion has been perplexing the psychological community due to the numerous challenges that stand in the way of achieving accurate objective measurements. Unlike conditions such as depression, where the f…
View article: Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial
Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years with Severe Atopic Dermatitis: Post Hoc Analysis Results from a Phase III Trial Open
View article: P40 Dupilumab treatment restores skin barrier function in lesional and nonlesional skin of patients with atopic dermatitis and improves patient-reported outcomes
P40 Dupilumab treatment restores skin barrier function in lesional and nonlesional skin of patients with atopic dermatitis and improves patient-reported outcomes Open
The objective of this analysis is to report the effect of dupilumab treatment on skin barrier function and patient-reported outcomes (PROs) in adults and adolescents with moderate-to-severe atopic dermatitis (AD). BALISTAD (NCT04447417) wa…
View article: Table of Contents
Table of Contents Open
View article: Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis
Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis Open
Background Atopic dermatitis (AD) is characterized by abnormal skin lipids that are largely driven by hyperactivated type 2 immune responses. The antibody to the α‐subunit of interleukin (IL)‐4 receptor, dupilumab, was recently approved to…
View article: Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data
Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis—A pooled analysis of trial data Open
Background/Objective Patients with moderate‐to‐severe atopic dermatitis (AD) have increased risk of cutaneous and extracutaneous infections. Dupilumab has previously been associated with reduced risk of serious/severe infections and non‐he…
View article: Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry
Disease characteristics, comorbidities, treatment patterns and quality of life impact in children <12 years old with atopic dermatitis: Interim results from the PEDISTAD Real-World Registry Open
To the Editor: To address the issue of limited real-world long-term data in children with atopic dermatitis (AD), we designed the PEDISTAD observational study (NCT03687359). This ongoing, international, longitudinal, 5-year registry assess…
View article: Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks
Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks Open
LIBERTY AD CHRONOS (NCT02260986).
View article: Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from seven randomized, placebo-controlled studies
Dupilumab treatment reduces hospitalizations in adults with moderate-to-severe atopic dermatitis: a pooled analysis of data from seven randomized, placebo-controlled studies Open
Introduction:Patients with atopic dermatitis (AD) may require inpatient hospital treatment for refractory AD, severe AD flares (exacerbations), and infections.Dupilumab (Dupixent®), a fully human monoclonal antibody that blocks the shared …
View article: Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial Open
To the Editor: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by flares, defined as worsening of the disease requiring escalation/intensification of AD treatment.1Sidbury R. Tom W.L. Bergman J.N. et al.Guidelin…
View article: Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology
Protocol for a prospective, observational, longitudinal study in paediatric patients with moderate-to-severe atopic dermatitis (PEDISTAD): study objectives, design and methodology Open
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disease often associated with atopic comorbidities and has significant impact on children and their families. There is a lack of robust and longitudinal long-term data on d…
View article: Low-cost diagnostic test for susceptible and drug-resistant tuberculosis in rural Malawi
Low-cost diagnostic test for susceptible and drug-resistant tuberculosis in rural Malawi Open
Background: Rural settings where molecular tuberculosis diagnostics are not currently available need easy-to-use tests that do not require additional processing or equipment. While acid-fast bacilli (AFB) smear is the most common and often…
View article: In Pursuit of Happiness: Creation of an Academic Hospitalist Wellness Committee and Well-being Survey
In Pursuit of Happiness: Creation of an Academic Hospitalist Wellness Committee and Well-being Survey Open
Physician burnout poses a critical threat to the delivery of healthcare. A solution to this problem is a leadership imperative. Managing demands on physicians can prevent burnout and foster engagement. This study assesses stress and burnou…
View article: Optimizing the net interest margin of a bank : An extension of the Black-Litterman model with financial regulations
Optimizing the net interest margin of a bank : An extension of the Black-Litterman model with financial regulations Open
A bank's business model is based on borrowing and lending, and by borrowing funds at a lower rate and lending these funds at a higher rate, the bank makes a profit. Thus, a key task in each bank's operations is to maximize its net interest…
View article: Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM
Efficacy and Tolerability of Delayed-release Dimethyl Fumarate in Black, Hispanic, and Asian Patients with Relapsing-Remitting Multiple Sclerosis: Post Hoc Integrated Analysis of DEFINE and CONFIRM Open
Introduction Clinical course and treatment response may vary according to race/ethnicity in multiple sclerosis (MS) patients. Delayed-release dimethyl fumarate (DMF; also known as gastro-resistant DMF) demonstrated significant efficacy and…
View article: Number Needed to Treat in Multiple Sclerosis Clinical Trials
Number Needed to Treat in Multiple Sclerosis Clinical Trials Open
Clinicians are expected to select a therapy based on their appraisal of evidence on benefit-to-risk profiles of therapies. In the management of relapsing-remitting multiple sclerosis (RRMS), evidence is typically expressed in terms of risk…
View article: Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS Open
This study provides Class IV evidence that first-line natalizumab for RRMS improves relapse rates and treatment persistence outcomes compared to first-line IFN-β/GA.
View article: Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies
Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing–Remitting Multiple Sclerosis: 6-Year Interim Results From an Extension of the DEFINE and CONFIRM Studies Open
ClinicalTrials.gov identifiers, NCT00835770 (ENDORSE); NCT00420212 (DEFINE); NCT00451451 (CONFIRM).
View article: Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP) Open
In this observational study, the disability progression rate decreased further beyond 2 years of natalizumab treatment. Patients who responded well and remained on continuous natalizumab therapy for over 4 years had sustained and potential…
View article: Comparative efficacy of switching to natalizumab in active multiple sclerosis
Comparative efficacy of switching to natalizumab in active multiple sclerosis Open
Using large, real-world, propensity-matched datasets we demonstrate that after a relapse on IFNβ or GA, switching to natalizumab (rather than between IFNβ and GA) led to superior outcomes for patients in all measures assessed. Results were…